(系统性肥大细胞增多症。分类,症状,治疗方法]。

Doris M Kraemer, Susanne M Grunewald, Annette Kolb-Mäurer
{"title":"(系统性肥大细胞增多症。分类,症状,治疗方法]。","authors":"Doris M Kraemer,&nbsp;Susanne M Grunewald,&nbsp;Annette Kolb-Mäurer","doi":"10.1007/s00063-004-1021-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Systemic mastocytoses are a group of diseases, which are characterized by accumulation and unusual growth of mast cells infiltrating two different organs or types of tissue. Two case reports are introduced.</p><p><strong>Classification: </strong>According to the new WHO classification of 2000, mastocytoses are separated into cutaneous and systemic mastocytoses. Systemic mastocytosis is subdivided into an indolent course with good prognosis and four subgroups with poor prognosis (systemic mastocytosis with associated clonal hematologic non-mast-cell disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma).</p><p><strong>Genetics: </strong>Systemic mastocytoses are clonal disorders of mast cells and their progenitor cells, which may show point mutations of the protooncogene c-kit. This gene codes for the stem cell receptor (CD117).</p><p><strong>Therapy: </strong>Therapy of systemic mastocytosis depends on patient's symptoms. There is no known cure of the disease. Besides diet and avoidance of skin irritations, symptoms are treated with H(1)- or H(2)-blockers, steroids, leukotriene receptor antagonists, and PUVA therapy. If patients suffer from systemic reactions such as hypotension or syncope, epinephrine solution should be prescribed for emergency use.</p>","PeriodicalId":18420,"journal":{"name":"Medizinische Klinik","volume":" ","pages":"131-6"},"PeriodicalIF":0.0000,"publicationDate":"2004-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00063-004-1021-x","citationCount":"2","resultStr":"{\"title\":\"[Systemic mastocytosis. Classification, symptoms, therapy].\",\"authors\":\"Doris M Kraemer,&nbsp;Susanne M Grunewald,&nbsp;Annette Kolb-Mäurer\",\"doi\":\"10.1007/s00063-004-1021-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Systemic mastocytoses are a group of diseases, which are characterized by accumulation and unusual growth of mast cells infiltrating two different organs or types of tissue. Two case reports are introduced.</p><p><strong>Classification: </strong>According to the new WHO classification of 2000, mastocytoses are separated into cutaneous and systemic mastocytoses. Systemic mastocytosis is subdivided into an indolent course with good prognosis and four subgroups with poor prognosis (systemic mastocytosis with associated clonal hematologic non-mast-cell disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma).</p><p><strong>Genetics: </strong>Systemic mastocytoses are clonal disorders of mast cells and their progenitor cells, which may show point mutations of the protooncogene c-kit. This gene codes for the stem cell receptor (CD117).</p><p><strong>Therapy: </strong>Therapy of systemic mastocytosis depends on patient's symptoms. There is no known cure of the disease. Besides diet and avoidance of skin irritations, symptoms are treated with H(1)- or H(2)-blockers, steroids, leukotriene receptor antagonists, and PUVA therapy. If patients suffer from systemic reactions such as hypotension or syncope, epinephrine solution should be prescribed for emergency use.</p>\",\"PeriodicalId\":18420,\"journal\":{\"name\":\"Medizinische Klinik\",\"volume\":\" \",\"pages\":\"131-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s00063-004-1021-x\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medizinische Klinik\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00063-004-1021-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medizinische Klinik","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00063-004-1021-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

背景:全身性肥大细胞增多症是一组以肥大细胞积聚和异常生长浸润两种不同器官或组织类型为特征的疾病。介绍了两例病例报告。分类:根据世界卫生组织2000年的新分类,肥大细胞增多症分为皮肤肥大细胞增多症和全身性肥大细胞增多症。全身性肥大细胞增多症可分为预后良好的无痛病程和预后不良的4个亚组(全身性肥大细胞增多症伴克隆性血液学非肥大细胞疾病、侵袭性全身性肥大细胞增多症、肥大细胞白血病和肥大细胞肉瘤)。遗传学:全身性肥大细胞病是肥大细胞及其祖细胞的克隆性疾病,可能表现为原癌基因c-kit的点突变。该基因编码干细胞受体(CD117)。治疗方法:全身性肥大细胞增多症的治疗取决于患者的症状。这种病没有已知的治疗方法。除了饮食和避免皮肤刺激外,症状还可以用H(1)-或H(2)-受体阻滞剂、类固醇、白三烯受体拮抗剂和PUVA治疗。如果患者出现全身反应,如低血压或晕厥,应开肾上腺素溶液紧急使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Systemic mastocytosis. Classification, symptoms, therapy].

Background: Systemic mastocytoses are a group of diseases, which are characterized by accumulation and unusual growth of mast cells infiltrating two different organs or types of tissue. Two case reports are introduced.

Classification: According to the new WHO classification of 2000, mastocytoses are separated into cutaneous and systemic mastocytoses. Systemic mastocytosis is subdivided into an indolent course with good prognosis and four subgroups with poor prognosis (systemic mastocytosis with associated clonal hematologic non-mast-cell disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma).

Genetics: Systemic mastocytoses are clonal disorders of mast cells and their progenitor cells, which may show point mutations of the protooncogene c-kit. This gene codes for the stem cell receptor (CD117).

Therapy: Therapy of systemic mastocytosis depends on patient's symptoms. There is no known cure of the disease. Besides diet and avoidance of skin irritations, symptoms are treated with H(1)- or H(2)-blockers, steroids, leukotriene receptor antagonists, and PUVA therapy. If patients suffer from systemic reactions such as hypotension or syncope, epinephrine solution should be prescribed for emergency use.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medizinische Klinik
Medizinische Klinik 医学-医学:内科
自引率
0.00%
发文量
0
期刊最新文献
[Liver--gallbladder]. [Iron deficiency]. [Frontotemporal dementia]. [Hepatic encephalopathy]. [ON CHILD ABUSE].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1